Cocaine Addiction Clinical Trial
Official title:
Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity and Use
The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The investigators will attempt to augment this effect by a) doubling the number of propranolol-medicated cocaine cue exposure (CCE) retrieval sessions and b) increasing the dose of propranolol. It is expected that propranolol treated groups, relative to placebo treated groups, will evidence greater reduction of craving, cue reactivity and cocaine use during follow-up cocaine cue exposures. Also, these effects will be greater for those who receive 80mg of propranolol as opposed to 40mg.
Three groups of CD (cocaine dependant) participants will receive two sessions of cocaine cue exposure (CCE), each separated by a 24 hr. period and both conducted while the participants remain in hospital. One group (PBO) will receive placebo following each CCE session while the second (40PP) and third (80PP) group will receive 40 mg and 80 mg propranolol, respectively. Participants will return two days, and 1, 3, and 6 weeks after discharge and will be administered a CCE session to assess for maintenance/generalization of disruption of reconsolidation (DoR) effects on craving and cue reactivity to familiar and novel cocaine cues. Participants will also be assessed 3 times weekly for cocaine use (self-report & urine drug screen) during follow-up. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04336293 -
sTMS for Substance Use-disordered Veterans
|
N/A | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Completed |
NCT01651377 -
Pramipexole as a Treatment for Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02768441 -
Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots
|
Early Phase 1 | |
Completed |
NCT02626494 -
Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction
|
Phase 4 | |
Recruiting |
NCT02892851 -
Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.
|
N/A | |
Not yet recruiting |
NCT01319214 -
Reducing Drug Craving Memories
|
N/A | |
Recruiting |
NCT01259362 -
Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients
|
Phase 2 | |
Completed |
NCT01211418 -
Integrative Meditation (IM) for Cocaine Addiction
|
N/A | |
Recruiting |
NCT03423667 -
Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction
|
Phase 2 | |
Completed |
NCT01984177 -
Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence
|
N/A | |
Completed |
NCT01887366 -
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
|
Phase 2 | |
Completed |
NCT01337297 -
Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction
|
Phase 1/Phase 2 | |
Completed |
NCT01067846 -
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
|
N/A | |
Completed |
NCT01651364 -
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
|
Phase 1 | |
Recruiting |
NCT03018236 -
Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
|
Phase 4 | |
Completed |
NCT01929343 -
Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
|
Phase 2 | |
Completed |
NCT01281202 -
Vigabatrin for the Treatment of Cocaine Dependency
|
Phase 2/Phase 3 |